Inventiva expanded its executive leadership as the company prepares for a Phase III readout in metabolic dysfunction-associated steatohepatitis (MASH). Inventiva appointed Axel-Sven Malkomes as CFO, succeeding Jean Volatier, who becomes EVP finance and corporate social responsibility. Susan Coles returns as chief legal officer, and Pamela Herbster becomes chief people officer. The changes come as Inventiva looks toward a Phase III readout in 4Q26 for lanifibranor in MASH, a pivotal timing window for corporate strategy, investor expectations, and operational planning. For employees and partners, the reshuffle also indicates the company is retooling governance capacity to handle late-stage trial execution and regulatory preparations.